Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

(NASDAQ:ARGX – Get Free Report) was upgraded by investment analysts at Sanford C. Bernstein from a “market perform” rating to ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Jones Financial Companies Lllp increased its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 1,016.7% during the fourth ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Bullous pemphigoid is an autoimmune skin disease characterized by tense blisters and erosions. In this Primer, Akbarialiabad et al. review the epidemiology, pathophysiology, diagnosis and ...

From wetting the bed to acne, we have crunched the numbers on the success rate of every single disability claim. It comes ...